BR112023016025A2 - Anticorpo anti-pd-l1 e uso dos mesmos - Google Patents

Anticorpo anti-pd-l1 e uso dos mesmos

Info

Publication number
BR112023016025A2
BR112023016025A2 BR112023016025A BR112023016025A BR112023016025A2 BR 112023016025 A2 BR112023016025 A2 BR 112023016025A2 BR 112023016025 A BR112023016025 A BR 112023016025A BR 112023016025 A BR112023016025 A BR 112023016025A BR 112023016025 A2 BR112023016025 A2 BR 112023016025A2
Authority
BR
Brazil
Prior art keywords
protein
binding
antibody
isolated antigen
drug
Prior art date
Application number
BR112023016025A
Other languages
English (en)
Inventor
Jianqiu Song
Sujun Deng
Xiaodan Cao
Xiaowu Liu
Xueping Wang
Zhongzong Pan
Zongda Wang
Original Assignee
Jiangxi Jemincare Group Co Ltd
Shanghai Jemincare Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Jemincare Group Co Ltd, Shanghai Jemincare Pharmaceutical Co Ltd filed Critical Jiangxi Jemincare Group Co Ltd
Publication of BR112023016025A2 publication Critical patent/BR112023016025A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

anticorpo anti-pd-l1 e uso do mesmo. é fornecida uma proteína isolada de ligação ao antígeno capaz de se ligar à proteína pd-l1, capaz de bloquear a ligação entre a proteína pd-1 e a proteína pd-l1 e/ou capaz de estimular as células imunes para secretar citocinas. também é fornecido o uso da proteína isolada de ligação ao antígeno na preparação de um fármaco.
BR112023016025A 2021-02-10 2022-02-09 Anticorpo anti-pd-l1 e uso dos mesmos BR112023016025A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110183554 2021-02-10
PCT/CN2022/075599 WO2022171108A1 (zh) 2021-02-10 2022-02-09 抗pd-l1抗体及其用途

Publications (1)

Publication Number Publication Date
BR112023016025A2 true BR112023016025A2 (pt) 2023-10-31

Family

ID=82838286

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023016025A BR112023016025A2 (pt) 2021-02-10 2022-02-09 Anticorpo anti-pd-l1 e uso dos mesmos

Country Status (10)

Country Link
EP (1) EP4293047A1 (pt)
JP (1) JP2024509369A (pt)
KR (1) KR20230169942A (pt)
CN (1) CN116848144A (pt)
AU (1) AU2022220089A1 (pt)
BR (1) BR112023016025A2 (pt)
CA (1) CA3210910A1 (pt)
IL (1) IL305101A (pt)
TW (1) TW202241958A (pt)
WO (1) WO2022171108A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104356236B (zh) * 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CN106243225B (zh) * 2015-06-11 2021-01-19 智翔（上海）医药科技有限公司 新型抗-pd-l1抗体
CN106432501B (zh) * 2015-08-06 2021-07-30 基石药业 新型抗pd-l1抗体
CN106432494B9 (zh) * 2015-08-11 2022-02-15 广州誉衡生物科技有限公司 新型抗-pd-1抗体
CN106699891B (zh) * 2017-01-25 2019-04-09 北京天广实生物技术股份有限公司 一种抗pd-l1抗体、其药物组合物及其用途
EP3645738A4 (en) * 2017-06-25 2021-08-18 Systimmune, Inc. ANTI-PD-L1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF
CN109970857B (zh) * 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN110156895B (zh) * 2019-05-30 2020-11-20 上海甲贝生物医药技术股份有限公司 一种抗pd-l1抗体或其功能性片段及其用途

Also Published As

Publication number Publication date
AU2022220089A1 (en) 2023-08-31
KR20230169942A (ko) 2023-12-18
TW202241958A (zh) 2022-11-01
WO2022171108A1 (zh) 2022-08-18
CN116848144A (zh) 2023-10-03
EP4293047A1 (en) 2023-12-20
IL305101A (en) 2023-10-01
CA3210910A1 (en) 2022-08-18
JP2024509369A (ja) 2024-03-01

Similar Documents

Publication Publication Date Title
EP3882275A4 (en) BIFUNCTIONAL ANTI-PD-1 AND ANTI-VEGFA ANTIBODIES, PHARMACEUTICAL COMPOSITION AND USE THEREOF
CO2021003724A2 (es) Proteínas de fijación a sirpα y métodos de uso de estas
BR112019022972A2 (pt) Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas
CO2021004534A2 (es) Proteínas de unión anti-cd38, anti-cd28, and anti-cd3 triespecíficas y métodos de uso para tratar una infección viral
EA202092945A1 (ru) Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии
TWI800854B (zh) 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
BR112017014742A2 (pt) preparações combinadas para o tratamento de câncer ou infecção
CO2020010345A2 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
CL2018002998A1 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
WO2017132562A8 (en) Antigen binding proteins that bind pd-l1
CL2023002105A1 (es) Dominios variables de anticuerpo que se dirigen a cd33 y sus usos
EP3954712A4 (en) BIFUNCTIONAL ANTI-PD-L1/VEGF ANTIBODIES AND THEIR USE
BR112021024820A2 (pt) Proteína de fusão bifuncional contra pdl1 e tgfss e uso da mesma
BR112018072953A2 (pt) polipeptídeos de fusão de cd40l-fc e métodos de uso dos mesmos
JOP20220163A1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
CL2019002953A1 (es) Anticuerpo anti-pd-l1 y uso del mismo.
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
BR112016024214B8 (pt) Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal
BR112019005944A2 (pt) anticorpos que se ligam à interleucina 2 e usos dos mesmos
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
CO2021001410A2 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
AR120222A1 (es) Anticuerpos dirigidos a flt3 y uso de los mismos